Key stats
About iShares NASDAQ US Biotechnology UCITS ETF
Home page
Inception date
Mar 6, 2018
Structure
Irish VCIC
Replication method
Physical
Dividend treatment
Distributes
Primary advisor
BlackRock Asset Management Ireland Ltd.
ISIN
IE00BDZVHG35
The investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the NASDAQ Biotechnology Index.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.78%
Health Technology96.17%
Commercial Services1.50%
Technology Services1.35%
Health Services0.74%
Process Industries0.02%
Bonds, Cash & Other0.22%
Cash0.15%
Mutual fund0.08%
Miscellaneous0.00%
Stock breakdown by region
North America82.77%
Europe16.87%
Asia0.29%
Oceania0.07%
Latin America0.00%
Africa0.00%
Middle East0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
BTEE invests in stocks. The fund's major sectors are Health Technology, with 96.17% stocks, and Commercial Services, with 1.50% of the basket. The assets are mostly located in the North America region.
BTEE top holdings are Vertex Pharmaceuticals Incorporated and Amgen Inc., occupying 7.75% and 7.67% of the portfolio correspondingly.
BTEE last dividends amounted to 0.02 USD. Six months before that, the issuer paid 0.01 USD in dividends, which shows a 43.50% increase.
BTEE assets under management is 27.76 M USD. It's fallen 4.90% over the last month.
BTEE fund flows account for −7.49 M USD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
Yes, BTEE pays dividends to its holders with the dividend yield of 0.43%. The last dividend (Jun 25, 2025) amounted to 0.02 USD. The dividends are paid semi-annually.
BTEE shares are issued by BlackRock, Inc. under the brand iShares. The ETF was launched on Mar 6, 2018, and its management style is Passive.
BTEE expense ratio is 0.35% meaning you'd have to pay 0.35% of your investment to help manage the fund.
BTEE follows the NASDAQ Biotechnology Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
BTEE invests in stocks.
BTEE price has risen by 6.52% over the last month, and its yearly performance shows a 8.21% increase. See more dynamics on BTEE price chart.
NAV returns, another gauge of an ETF dynamics, have risen by 6.36% over the last month, showed a 16.74% increase in three-month performance and has increased by 7.47% in a year.
NAV returns, another gauge of an ETF dynamics, have risen by 6.36% over the last month, showed a 16.74% increase in three-month performance and has increased by 7.47% in a year.
BTEE trades at a premium (0.01%) meaning the ETF is trading at a higher price than the calculated NAV.